Key result
Coronary microvascular disease is present in 30% of patients with angina and is associated with increased morbidity and mortality, with emerging evidence supporting physiology-stratified management.
Why the study?
Despite major advances in diagnosing and stratifying coronary microvascular disease, therapeutic strategies remain limited and poorly defined.
This review highlights that while diagnostic capabilities for coronary microvascular disease have improved, therapeutic strategies remain limited and poorly defined.
May support testing-guided CMD care; leaves open standardized therapies for prospective trials.
Coronary microvascular disease (CMD) is present in 30% of patients with angina and is associated with increased morbidity and mortality. We now have an improved understanding of the pathophysiology of CMD and the invasive and noninvasive tests that can be used to make the diagnosis. Recent studies have shown that management of CMD guided by physiological testing yields better results than empirical treatment. Despite major advances in diagnosing and stratifying this condition, therapeutic strategies remain limited and poorly defined. This review article discusses recent advances in understanding the pathophysiology of CMD, the modalities that are available to diagnose it clinically, current management options and a look at what is in store for the future.
No takes yet. Share an insight, caveat, or question.
Sinha et al. (2020) conducted a review in Coronary microvascular disease. Coronary microvascular disease is present in 30% of patients with angina and is associated with increased morbidity and mortality, with emerging evidence supporting physiology-stratified management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: